Characteristics | Pregnancies, n = 309 | Patients, n = 261 |
---|---|---|
Race | ||
White | 184 (60) | 151 (58) |
Black | 93 (30) | 80 (31) |
Other | 32 (10) | 30 (11) |
Education, yrs | ||
High school, ≤ 12 | 101 (33) | 81 (31) |
College or university, 13–16 | 141 (46) | 120 (46) |
Postgraduate, > 16 | 67 (22) | 60 (23) |
Pregnancy outcome date | ||
Prior to January 1999 | 117 (38) | |
January 1999–February 2015 | 192 (62) | |
Medication use during pregnancy* | ||
Low-dose aspirin | 162 (52) | |
Hydroxychloroquine | 184 (60) | |
Immunosuppressant | 48 (15) | |
Prednisone | 160 (51) | |
Prednisone ≥ 7.5 mg/day among prednisone users | 116 (73) | |
No medications | 22 (7) | |
Clinical characteristics | ||
Renal involvement during pregnancy (LAI > 1) | 79 (26) | |
Elevated serum creatinine during pregnancy, >1 | 24 (8) | |
High PGA during pregnancy (PGA ≥ 2) | 49 (16) | |
SDI ≥ 1 at conception | 114 (37) | |
Low C3 during pregnancy | 74 (24) | |
Low C4 during pregnancy | 106 (34) | |
Anti-dsDNA+ during pregnancy | 115 (37) | |
Age at conception, yrs | 29.9 (26.7–33.2) | |
Disease duration, yrs | 5.5 (2.1–9.3) | |
Highest PGA during pregnancy (scale 0–3) | 1.0 (0.5–1.5) | |
SDI at conception | 0 (0–3) | |
Highest daily prednisone dose during pregnancy, mg | 2.5 (0–15.0) | |
BMI, kg/m2 | 24.3 (21.3–29.2) | |
Total cholesterol, mg/dl | 162.0 (142.0–184.0) | |
Systolic BP, mmHg | 116.0 (106.0–126.0) | |
Diastolic BP, mmHg | 70.0 (64.0–80.0) |
↵* Categories are not mutually exclusive: women can be in multiple categories; therefore, percentages add up to > 100%. IQR: interquartile range; PGA: physician’s global assessment; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; BMI: body mass index; BP: blood pressure.